AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18937965
Drug: Reversible P2Y12
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reversible P2Y12 receptor antagonists
Trial: 15525860
Drug: Watchful Waiting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watchful Waiting Intervention (WWI) - 5 weekly intervention calls from a nurse
Trial: 2752179
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous gamma-globulin (400 mg/kg on days 1 through 5)
Trial: 2752179
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral prednisone and high-dose intravenous gamma-globulin
Trial: 165913
Drug: ethinyl oestradiol
RxNorm normalized name: 17-ethinyl-3,17-oestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ethinyl oestradiol 20 mug daily
Trial: 165913
Drug: ethinyl oestradiol
RxNorm normalized name: 17-ethinyl-3,17-oestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ethinyl oestradiol 50 mug daily
Trial: 165913
Drug: conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conjugated equine oestrogens (Premarin) 0.625 mg daily
Trial: 165913
Drug: conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conjugated equine oestrogens (Premarin) 1.25 mg daily
Trial: 26149210
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL articaine (4% with 1:100,000 epinephrine)
Trial: 26149210
Drug: 3.6 mL
RxNorm normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mL articaine (4% with 1:100,000 epinephrine)
Trial: 22453111
Drug: Repeat onabotulinum
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat onabotulinum toxin A injections (both doses)
Trial: 19207293
Drug: sTfR levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sTfR levels (3.50 +/- 0.07 mg/l)
Trial: 7489418
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of plain bupivacaine with buprenorphine
Trial: 6283800
Drug: Fibre rich
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre rich breakfast (whole grain bread and whole apples, 8.4 g dietary fibre)
Trial: 6283800
Drug: Fibre poor
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre poor breakfast (white bread and apple juice, 3.1 g dietary fibre)
Trial: 23134880
Drug: Dietary supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplements and usual diet (group 2)
Trial: 20155838
Drug: Combination antibiotics
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antibiotics (doxycycline and rifampin)
Trial: 20155838
Drug: Combination antibiotics
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antibiotics
Trial: 12768894
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 4% sodium chondroitin sulfate and 3% sodium hyaluronate
Trial: 10172394
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural block with 1.2 mL/kg of 0.25% bupivacaine
Trial: 2025147
Drug: Low-intensity treatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity treatment (self-help booklet and 20-30 minute session with a trained counselor)
Trial: 2025147
Drug: High-intensity treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity treatment (low-level treatments plus individually tailored follow-up treatments)
Trial: 7469210
Drug: Minocycline, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline, 100 mg once or twice daily for 7 or 21 days
Trial: 30904540
Drug: Intrastromal voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrastromal voriconazole (ISV) injection
Trial: 30904540
Drug: Topical natamycin
RxNorm normalized name: Natamycin
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical natamycin alone
Trial: 22226309
Drug: Homeopathy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathy treatment (individualized homeopathic medicines in fifty millesimal (LM) potencies)
Trial: 22226309
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (including analgesics, antipyretics, and anti-inflammatory drugs)
Trial: 12860733
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with methotrexate (MTX) and sulfasalazine (SSZ) during the first year
Trial: 12860733
Drug: Single disease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single disease modifying antirheumatic drug treatment
Trial: 1588147
Drug: PRP vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP vaccine
Trial: 24612546
Drug: AST1306 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST1306 at 1000 mg BID
Trial: 24612546
Drug: AST1306 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST1306 at 1500 mg BID
Trial: 24612546
Drug: AST1306 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST1306 at 800 mg TID
Trial: 24612546
Drug: AST1306 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST1306 at 1200 mg TID
Trial: 24612546
Drug: AST1306 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST1306 (various doses)
Trial: 19880790
Drug: rhIGF-I (40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF-I (40, 80, or 120 microg/kg, administered sc, twice daily)
Trial: 19880790
Drug: rhIGF-I treatment
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIGF-I treatment
Trial: 15604947
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of fractional change during treatment
Trial: 12020483
Drug: PTMR plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTMR plus maximal medical therapy (MMT)
Trial: 9665202
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN) maintenance treatment at a starting dose of 3 mU/m2 three times per week.
Trial: 9665202
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN) maintenance treatment.
Trial: 9665202
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN) maintenance treatment and No treatment (control group).
Trial: 2681410
Drug: Felodipine conventional
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine conventional (5 mg twice a day)
Trial: 2681410
Drug: Felodipine extended
RxNorm normalized name: Felodipine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine extended release (10 mg once daily)
Trial: 4479277
Drug: High-volume feeds
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume feeds (230 ml/kg/day of S.M.A. S26 milk)
Trial: 4479277
Drug: Conventional feeds
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional feeds (180 ml/kg/day of S.M.A. S26 milk)
Trial: 31860387
Drug: PQQ (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PQQ (20 mg/day)
Trial: 26790796
Drug: Periarticular mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periarticular mixture of drugs (bupivacaine, ketorolac, morphine, adrenaline)
Trial: 17245476
Drug: Thiazolidinedione (e.g.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazolidinedione (e.g., pioglitazone)
Trial: 14512874
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (RBV) monotherapy
Trial: 14512874
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (IFN-alpha) monotherapy
Trial: 10436945
Drug: Nilestrioli 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilestrioli 2 mg twice a month and Perphenazine 12 mg and Doxepin 75 mg per day
Trial: 10436945
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid 300 mg a day
Trial: 2956874
Drug: Oral enoximone
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enoximone (150 mg 3 times daily)
Trial: 2956874
Drug: Intravenous enoximone
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enoximone (0.75 mg/kg)
Trial: 31396995
Drug: PBK-1701TC (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBK-1701TC (320 mg simethicone)
Trial: 28743135
Drug: Microsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsurgical treatment
Trial: 26418341
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg twice-daily plus Vitamin D3 1,000 IU twice-daily
Trial: 21669891
Drug: Specialized care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized care group with brief physician training and computer-assisted medication management
Trial: 15312348
Drug: Vp‐16 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vp‐16 1000 mg/m(2) with rhG‐CSF 300 microg.body(‐1).day(‐1)
Trial: 15312348
Drug: Vp‐16 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vp‐16 1500 mg/m(2) with rhG‐CSF 300 microg.body(‐1).day(‐1)
Trial: 15312348
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly defined, but implied as the comparison group receiving different Vp‐16 dosage)
Trial: 15994253
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nebulised salbutamol
Trial: 11514693
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of salbutamol and ipratropium
Trial: 9297994
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (nitrendipine 10-40 mg daily, possibly with enalapril 5-20 mg daily and hydrochlorothiazide 12.5-25.0 mg daily)
Trial: 3556957
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg every 6 h intravenously and colloidal aluminium phosphate 11 g every 4 h per os
Trial: 3556957
Drug: No preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preventive treatment
Trial: 30322408
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients who never achieved drug-free status)
Trial: 26420761
Drug: Standard anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anaesthetic treatment (Control)
Trial: 25192393
Drug: Argentine tango
RxNorm normalized name: Argentine canola pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argentine tango (AT) class, 1 hour twice weekly for 2 years
Trial: 12848633
Drug: Omeprazole, 10
RxNorm normalized name: Omeprazole, 10 mg oral delayed release capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 10 or 20 mg once daily for 4 weeks
Trial: 10827369
Drug: Lotrafiban (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafiban (up to 50 mg twice daily)
Trial: 10827369
Drug: Aspirin (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (standard therapy)
Trial: 8890722
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no thyroxine administration)
Trial: 8448808
Drug: Ioxaglate (ionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxaglate (ionic contrast agent)
Trial: 8448808
Drug: Iohexol (nonionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol (nonionic contrast agent)
Trial: 8448808
Drug: Nonionic agent
RxNorm normalized name: LANOLIN DERIVATES,NONIONIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonionic agent (iohexol)
Trial: 3519243
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 75 mg/day
Trial: 3519243
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination tablet containing 5 mg amiloride and 50 mg hydrochlorothiazide (Moduretic)
Trial: 3519243
Drug: Amiloride 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 15 mg/day added to hydrochlorothiazide
Trial: 3519243
Drug: Amiloride reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride reduced to 7.5 mg/day using Moduretic
Trial: 25566573
Drug: Topical suspension
RxNorm normalized name: Topical Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical suspension formulation of calcipotriene 0.005%‐betamethasone dipropionate 0.064%
Trial: 25566573
Drug: Ointment formulation
RxNorm normalized name: mineral oil / petrolatum / phenylephrine hydrochloride Rectal Ointment [Formulation R Ointment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment formulation of calcipotriene 0.005%‐betamethasone dipropionate 0.064%
Trial: 25566573
Drug: Topical suspension
RxNorm normalized name: Topical Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical suspension formulation
Trial: 18702951
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 or 30 mg/d for 6 months)
Trial: 18702951
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 or 750 mg/d for 6 months)
Trial: 10584050
Drug: (15)NH(4)Cl (3.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (15)NH(4)Cl (3.45 mg (15)N*kg(‐)(1)*d(‐)(1))
Trial: 10584050
Drug: (15)NH(4)Cl (3.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (15)NH(4)Cl (3.9 mg (15)N*kg(‐)(1)*d(‐)(1))
Trial: 1808500
Drug: Piracetam (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (9 g daily) in group I
Trial: 1808500
Drug: Piracetam (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (2.4 g daily) in group II
Trial: 16135859
Drug: Risperidone (1-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1-6 mg per day)
Trial: 11840417
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy agents (gemcitabine, topotecan, liposomal doxorubicin, prolonged oral etoposide) with platinum
Trial: 1378147
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg
Trial: 3572208
Drug: Labetalol 400
RxNorm normalized name: labetalol 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 400 mg
Trial: 8527263
Drug: Carvedilol 6.25
RxNorm normalized name: carvedilol 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 6.25 mg
Trial: 7908256
Drug: Carvedilol 12.5
RxNorm normalized name: carvedilol 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5 mg
Trial: 30832617
Drug: Olaparib combined
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib combined with temozolomide (TMZ) and intensity modulated radiotherapy (IMRT) for 6 weeks, followed by Olaparib as a single agent for 4 weeks during the radiotherapy period.
Trial: 29179649
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 100 million allo-hMSCs
Trial: 29179649
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 200 million allo-hMSCs
Trial: 23550906
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg UPA
Trial: 23550906
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg UPA
Trial: 23550906
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg UPA
Trial: 15117982
Drug: Fulvestrant (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant (250 mg, intramuscular injection, once monthly)
Trial: 15117982
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg, orally, once daily)
Trial: 15117982
Drug: Fulvestrant (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant (250 mg, intramuscular injection, once monthly) in ER+/PgR+ subgroup
Trial: 15117982
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg, orally, once daily) in ER+/PgR+ subgroup
Trial: 11694699
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro before breakfast
Trial: 11694699
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro before dinner
Trial: 11694699
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro after meals
Trial: 11694699
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin before meals
Trial: 8198411
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (500 mg/kg)
Trial: 2898256
Drug: ICI 118,551,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118,551, 50 mg orally given thrice daily
Trial: 28912210
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of evidence-based medications
Trial: 23621289
Drug: Enteral feeds
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral feeds 80 mL/kg/day started within 1 h of birth, increased by 20 mL/kg/day to 180 mL/kg/day, no intravenous fluids
Trial: 23621289
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluids 50 mL/kg/day started along with enteral feeds 30 mL/kg/day within 1 h of birth, increased by 20 mL/kg/day to 180 mL/kg/day
Trial: 16404409
Drug: Insulin quartiles
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin quartiles
Trial: 14504182
Drug: Clopidogrel with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel with aspirin dose ≤100 mg
Trial: 14504182
Drug: Clopidogrel with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel with aspirin dose 101-199 mg
Trial: 14504182
Drug: Clopidogrel with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel with aspirin dose ≥200 mg
Trial: 14504182
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with aspirin dose ≤100 mg
Trial: 14504182
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with aspirin dose 101-199 mg
Trial: 14504182
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with aspirin dose ≥200 mg
Trial: 8962903
Drug: Enteral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutritional support supplement (1680 calories, 294 grams of carbohydrates, 36.9 grams of fat, 43.5 grams of protein in branched chain amino acids)
Trial: 8962903
Drug: Enteral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutritional support supplement